Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?

Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill

“…In this regards, the combination of HZT and amlodipine (AML), a calcium channel blocker, with an angiotensin inhibitor, such as benazepril, ramipril or losartan (LS), is very effective to decrease the rate of cardiovascular events (Jamerson et al, 2008). Moreover, if the polypill containing a cholesterol lowering drug, it can be reduced by 80% the risk of CVD in patients with vascular disease (Chrysant and Chrysant, 2014;Exaire-Murad et al, 2015;Gadepalli et al, 2014;Katsiki et al, 2013;Wald and Law, 2003;Yusuf, 2002). Likewise, in a prevention trial of a polypill composed by AML, LS, HTZ, and simvastatin (SV), the mean systolic blood pressure was reduced by 12%, the diastolic blood pressure by 11%, and low-density lipoprotein (LDL) cholesterol by 39% (Wald et al, 2012).…”

Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients

“…There were very few CVD events 4 and considerable benefits on several factors, such as renal function and reduced serum uric acid levels 5 . We support combination treatments for CVD risk reduction 6,7 , especially with single pill formulations 8 . Indeed single pill combinations were embraced by a number of clinicians and researchers to address vascular risk [9][10][11] .…”

The Effectiveness of Polypill for the Prevention of Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials

“…Fixed-dose combination (FDC) therapies, also known as polypills, represent a medication that combines multiple active pharmaceutical ingredients into complex formulations [8,9]. Proposed by Wald and Law, this method delivers active ingredients to reduce CVD risk in a single-dose form, including a blood pressurelowering medication, a lipid-regulating medication, and a serum homocysteine-lowering medication, with or without the addition of an antiplatelet medication.…”